Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 23, 2023
Reporting Period: Event date February 23, 2023
This filing reports the adoption of the Fourth Amended and Restated By-laws by the Board of Directors, effective immediately.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance amendments and does not contain financial statements or performance data.
Material Changes
The primary material change is the amendment to the Company's By-laws. Key provisions include:
- Implementation of rules for stockholder action by written consent, including record date procedures and election inspector requirements.
- Elimination of outdated provisions governed by the Delaware General Corporation Law.
- Limitation of indemnification obligations for proceedings commenced by a person unless authorized by the Board.
- Reduction of indemnification or expense advancement obligations for directors/officers serving other entities by amounts collected from those entities.
- Requirement of a majority vote of outstanding shares entitled to vote to alter, amend, or repeal the By-laws.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on operations, specific risks, contingencies, or unusual items. The document is a procedural report regarding corporate by-laws.
Key Facts for Investor Verification
- Verify the full text of the Fourth Amended and Restated By-laws filed as Exhibit 3.1.
- Review the marked copy of the By-laws (Exhibit 3.2) to understand specific textual changes.
- Confirm the impact of the new written consent rules on future stockholder actions.
- Note the increased voting threshold (majority of outstanding shares) required for future By-law amendments.